Advancements of Prussian blue-based nanoplatforms in biomedical fields: Progress and perspectives

Y Wang, Z Liang, Z Liang, W Lv, M Chen… - Journal of Controlled …, 2022 - Elsevier
Prussian blue (PB) nanoparticles possess excellent physicochemical properties, including
imaging features, robust photothermal conversion ability, catalytic activity, surface …

Macrophage subsets and their role: co-relation with colony-stimulating factor-1 receptor and clinical relevance

S Yadav, A Priya, DR Borade, R Agrawal-Rajput - Immunologic Research, 2023 - Springer
Macrophages are one of the first innate immune cells to reach the site of infection or injury.
Diverse functions from the uptake of pathogen or antigen, its killing, and presentation, the …

Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC)

J Huang, Q Wu, DA Geller, Y Yan - Journal of Translational Medicine, 2023 - Springer
The pivotal role of the tumor microenvironment (TME) in the initiation and advancement of
hepatocellular carcinoma (HCC) is widely acknowledged, as it fosters the proliferation and …

New hope for tumor immunotherapy: the macrophage-related “do not eat me” signaling pathway

H Deng, G Wang, S Zhao, Y Tao, Z Zhang… - Frontiers in …, 2023 - frontiersin.org
The “do not eat me” signaling pathway is extremely active in tumor cells, providing a means
for these cells to elude macrophage phagocytosis and escape immune surveillance …

Inhibition of phospholipase D1 induces immunogenic cell death and potentiates cancer immunotherapy in colorectal cancer

WC Hwang, D Song, H Lee, C Oh, SH Lim… - … & Molecular Medicine, 2022 - nature.com
Phospholipase D (PLD) is a potential therapeutic target against cancer. However, the
contribution of PLD inhibition to the antitumor response remains unknown. We developed a …

Roles of exosomes as drug delivery systems in cancer immunotherapy: a mini-review

Z Fang, Y Ding, Z Xue, P Li, J Li, F Li - Discover Oncology, 2022 - Springer
Exosomes can be released by a variety of cells and participate in intercellular
communication in many physiological processes in the body. They can be used as carriers …

Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy

P Czajka-Francuz, MJ Prendes, A Mankan… - Frontiers in …, 2023 - frontiersin.org
The efficacy of cancer therapies is limited to a great extent by immunosuppressive
mechanisms within the tumor microenvironment (TME). Numerous immune escape …

[HTML][HTML] C-Myc-induced hypersialylation of small cell lung cancer facilitates pro-tumoral phenotypes of macrophages

L Tian, H Li, P Zhao, Y Liu, Y Lu, R Zhong, Y Jin, T Tan… - Iscience, 2023 - cell.com
Immunosuppressive myeloid cell populations have been documented in small cell lung
cancer (SCLC) subtypes, playing a key role in remolding the tumor microenvironment (TME) …

Interaction of RARRES1 with ICAM1 modulates macrophages to suppress the progression of kidney renal clear cell carcinoma

X Geng, K Chi, C Liu, Z Fu, X Wang, L Meng… - Frontiers in …, 2022 - frontiersin.org
Background RARRES1 is a tumor suppressor protein, and its expression is suppressed in
various tumor cells. However, whether it participates in the immune response in kidney renal …

Targeting myeloid checkpoint molecules in combination with antibody therapy: a novel anti-cancer strategy with IgA antibodies?

C Chan, M Lustig, N Baumann, T Valerius… - Frontiers in …, 2022 - frontiersin.org
Immunotherapy with therapeutic antibodies has shown a lack of durable responses in some
patients due to resistance mechanisms. Checkpoint molecules expressed by tumor cells …